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ST3Gal1 is a key sialyltransferase which adds α2,3-linked sialic acid to substrates and generates core 1 O-glycan structure.
Upregulation of ST3Gal1 has been associated with worse prognosis of breast cancer patients. However, the protein substrates
of ST3Gal1 implicated in tumor progression remain elusive. In our study, we demonstrated that ST3GAL1-silencing significantly
reduced tumor growth along with a notable decrease in vascularity of MCF7 xenograft tumors. We identified vasorin (VASN)
which was shown to bind TGF-β1, as a potential candidate that links ST3Gal1 to angiogenesis. LC-MS/MS analysis of VASN
secreted from MCF7, revealed that more than 80% of its O-glycans are sialyl-3T and disialyl-T. ST3GAL1-silencing or
desialylation of VASN by neuraminidase enhanced its binding to TGF-β1 by 2- to 3-fold and thereby dampening TGF-β1
signaling and angiogenesis, as indicated by impaired tube formation of HUVECs, suppressed angiogenesis gene expression
and reduced activation of Smad2 and Smad3 in HUVEC cells. Examination of 114 fresh primary breast cancer and their adjacent
normal tissues showed that the expression levels of ST3Gal1 and TGFB1 were high in tumor part and the expression of two
genes was positively correlated. Kaplan Meier survival analysis showed a significantly shorter relapse-free survival for those
with lower expression VASN, notably, the combination of low VASN with high ST3GAL1 yielded even higher risk of recurrence
(p = 0.025, HR = 2.967, 95% CI = 1.14–7.67). Since TGF-β1 is known to transcriptionally activate ST3Gal1, our findings
illustrated a feedback regulatory loop in which TGF-β1 upregulates ST3Gal1 to circumvent the negative impact of VASN.
Introduction
In breast cancer, the upregulation of ST3 beta-galactoside alpha-
2,3-sialyltransferase 1 (ST3Gal1) terminates core 1 structure by
adding α2,3-linked sialic acid to Gal1-3GalNac-1-O-Ser/Thr,1,2
while in normal breast tissue, C2GnT1 is the key enzyme adding
GlcNAc to GalNAc on core 1 (GalB1–3GalNAc-Ser/Thr) to
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generate extended core 2 structures. Accordingly, ST3Gal1 and
increased amount of truncated O-glycans were detected in
glioblastomas,3 hepatocellular carcinoma,4 colorectal cancer,5
bladder cancer6 and conferred poor prognosis in patients.7 Par-
ticularly, elevation of ST3Gal1 was detected in breast cancer and
correlated with increased tumor grade.8 However, the protein
substrates of ST3Gal1 involved in tumor progression remain
elusive.
In our study, we identified vasorin (VASN) as a ST3Gal1
substrate protein. VASN is a type I membrane protein of
673 amino acids containing tandem arrays of leucine-rich
repeat motif, an epidermal growth factor-like motif, and a
fibronectin type III-like motif at the extracellular domain. The
soluble or secreted VASN released by ADAM179 was reported
to affect vascular pathophysiology by trapping TGF-β1 at the
extracellular level without significantly impacted TGF-β recep-
tor complexes.10 However, the role of VASN in tumor angio-
genesis has never been explored. Up to date, only a few
studies on VASN have been associated with cancer. Li et al.,
reported an elevated circulating level of VASN was detected in
patients with hepatocellular carcinoma.11 Huang et al., found
that VASN-containing exosomes promoted the migration of
recipient human umbilical vein endothelial cells (HUVECs).12
Recently, a report reveal that VASN is critical to maintaining
glioma stem-like cells in hypoxia.13 However, the role of
VASN in cancer remains enigmatic.
In our study, we identified VASN as the ST3Gal1 target pro-
tein. Sialyl-3 T and disialyl-T are the majority of the O-glycan of
VASN. Overexpression of VASN in ST3Gal1-silenced cells
greatly inhibited TGF-β1-induced Smad2/3 signaling in
HUVEC, implicating that ST3Gal1 mediated sialylation is criti-
cal for VASN bind to TGF-β1. Finally, the gene expression of
ST3Gal 1 (encoded by ST3GAL1), VASN (VASN) and TGF-β1
(TGFB1) in breast cancer samples and their clinical correlations
were evaluated.
Material and Method
Clinical specimens
Fresh primary breast cancer tumor and adjacent normal tissue
specimens were collected from 114 patients during surgical
resections performed at the Tri-Service General Hospital
(Taipei, Taiwan). Informed consent was obtained from all sub-
jects before their tissue were deposited. The sample were fully
encoded and used under a protocol approved by the Institu-
tional Review Board of Human Subjects Research Ethics Com-
mittee of the Tri-Service General Hospital and Chang Gung
Memorial Hospital (Taoyuan, Taiwan). The clinicopathologic
information is described by Fan et al.14
Experimental procedures
Female NSG mice (8–12 weeks old) were purchased from the
Jackson Laboratory (Maine, USA). All animals were housed
under specific pathogen-free conditions in the Animal Center of
Chang Gung University and studies were approved by the Insti-
tutional Animal Care and Use Committee of the University.
Cells, antibodies and recombinant proteins
Human breast cancer cell lines MCF7 was purchased from
American Type Culture Collection (Rockville, Maryland USA)
and maintained in DMEM supplemented with 10% FBS. The
after antibodies were used in the study: Biotinylated antihuman
Vasorin antibody (BAF2140, R&D Systems, Minneapolis,
MN), SLITL2 (#7468–1, Abcam, CA), antimouse CD31 (BD
Pharmingen, San Jose, CA, 550274), Streptavidin Peroxidase
Labeled (474–3,000, KPL, Gaithersburg, MD USA), Smad2/3
(#5678, Cell Signaling, Danvers, MA USA), and pSmad2 (#8828
Cell Signaling), pSmad3 (#1880-S-Ex, Epitomics, Burlingame,
CA). Recombinant Human Transforming Growth Factor -β1/
TGF-β1 (rhTGFβ-1; CA59) and Human Vasorin (C394) were
purchased from Novoprotein (Summit, NJ).
Small interference RNA (siRNA) or short hairpin RNA (shRNA)
plasmid transfection
Control pLAS.Void (pVoid), and ST3Gal1 shRNA
(TRCN0000231843) plasmids were purchased from the RNAi
core (Academia Sinica, Taipei, Taiwan). The transfection was
performed as described.14 MCF7 cells stably expressing
ST3Gal1 (AGAGACTTGAGTGGCGATTAC) or control pVoid
shRNAs were maintained in media with puromycin (2 μg/mL).
Control scramble siRNA (sc) and siRNA (si) oligonucleotides
(UCACUCUGAUCUUUGCAGGAACCGG and CCGGUUC-
CUGCAAAGAUCAGAGUGA.) directed against ST3Gal1 were
purchased from Invitrogen (Carlsbad, CA). Cells were trans-
fected with siRNA oligonucleotides using Lipofectamine RNAi-
MAX (Invitrogen) and incubated at 37 C for 48 h.
In-gel reductive β-elimination
sVASN from MCF7 medium was immunopurified using anti-
VASN antibody and separated by SDS-PAGE. VASN bands were
excised from the PAGE and cut into (1 mm × 1 mm) pieces, fol-
lowed by PNGase F (New England BioLabs, Hertfordshire,UK)
digestion overnight at 37 C.16 The released N-glycan was
What’s new?
The addition of sialic acid to glycoproteins is dysregulated in many cancers, and enhanced expression of one key enzyme, the
sialyltransferase ST3Gal1, is associated with poor prognosis. Here, the authors identified the membrane protein vasorin as a
new ST3Gal1 substrate and connect it with TGF-β1-induced signaling and angiogenesis in breast cancer. As silencing of
ST3Gal1 dampened TGF-β1 signaling and suppressed angiogenesis, development of ST3Gal1 inhibitors might be clinically
useful to improve the prognosis of breast cancer patients.
Yeo et al. 1997
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removed by washing several times with pure water and 50%
acetonitrile solution. VASN in the gel was then subjected to
β-elimination to remove O-glycans as previously described.17
In short, the gel was soaked in 1 M sodium borohydride in
100 mM sodium hydroxide solution overnight at 45 C, and
the reaction was quenched by adding drops of glacial acetic
acid. The solution containing the O-glycans was aliquoted
and desalted using Dowex 50Wx8 (H+ form) ion exchange
resin. Excess borate was removed in a nitrogen blow dryer
by co-evaporation with 10% (v/v) acetic acid in methanol.
Prior to permethylation and MS analysis, all extracts were
dried in a SpeedVac and kept at −30 C.
Glycan permethylation, nanoflow LC–MS/MS analysis, and
the MS data mining
Permethylation of O-glycans was conducted using the NaOH/
DMSO slurry method and iodomethane.16 The permethylated
derivatives were extracted using a chloroform/water method
and purified by ZipTip-C18 tips. The permethylated glycans
nanoflow LC–MS/MS experiments were performed using a
reverse phase C18 capillary column (75 μm × 25 cm packed
with ReproSil-Pur basic C18, 1.9 μm) and an Orbitrap Fusion
mass spectrometer (Thermo Scientific) equipped with a nanoe-
lectrospray ion source (New Objective) and an UltiMate 3,000
RSLCnano system pump (Thermo Scientific Dionex). The
nanoflow LC for the separation of O-glycans was conducted at
a flow rate of 300 nL/min with a linear gradient from 25%
(v/v) acetonitrile to 55% (with 0.1% formic acid) in 45 min.
The nanoelectrospray source was powered in the range of
1.6–1.8 kV. The scan cycle was performed in top-speed mode
within a cycle time of 3 s, which can intelligently schedule MS
and data-dependent MS/MS scans. The full-scan MS (m/z
300–1,500) experiment was performed in the Orbitrap at a
resolution of 120 K and an automatic gain control (AGC) tar-
get value of 4 × 1018, while the data-dependent MS/MS
experiments was conducted in the C-trap using higher energy
collisional dissociation (HCD) with 15% normalized collision
energy at a resolution of 15 K and an AGC value of 5 × 108.
To process MS data for the structural characterization of
O-glycans from sVASN, we used the X-tract program to con-
duct peak deconvolution and output the peaklist with decon-
voluted m/z and intensity using Xcalibur software from the
raw MS data files. We next loaded the peaklist into the
analytic module of GlycoWorkbench to annotate peak with
glycan structure from the database of CFG according to the
MS correlation with 5 ppm tolerance.18 We manually exam-
ined the MS/MS spectra of matched O-glycan structures and
annotated the carbohydrate fragmentation based on the
nomenclature proposed by Domon and Costello.19 We also
manually calculated the peak area in corresponding monoiso-
topic peak XICs to obtain the abundance of each glycoform.
The relative abundance of individual glycoform was calculated
based on the percentage (%) of sum integrated peak areas
from all of the identified O-glycoforms shown in Supporting
Information Table S1. The results were conducted from two
technical repeats.
Endothelial cell tube formation
The endothelial cell tube formation assay was performed as
previously described.20 Matrigel (BD, Bedford, MA) was
added to 48-well plates in a volume of 150 μL and allowed to
solidify at 37 C for 30 min. HUVECs (15 K cells/well) were
suspended in 50% CM and 50% regular medium (EGM-2,
Lonza, Walkersville, MD) before addition to Matrigel-
precoated plates. After 14 h, the formation of the capillary-like
tube network by HUVECs was imaged using phrase-contrast
microscopy, and the junctions and meshes of the network
were quantified using ImageJ software.
Immunohistochemistry for CD31
Xenografted tumors were first fixed with zinc solution (550,523,
BD Pharmingen) for 24 h. Tumors were embedded and dissected
into 5 μm thick sections, followed by de-waxing and blocking with
3% H2O2. The blood vessels in tumor sections were stained by
purified rat antimouse CD3121 antibody (1:20, 550,274, BD Phar-
mingen) overnight at 4 C. The detection was followed by
polymer-HRP IHC system and sections were counterstained with
methyl green (1%). Digital images were captured by an Aperio
ScanScope XT Slide Scanner (Aperio Technologies, Vista, CA)
under 20-fold magnification. The DAB-positive areas were quanti-
fied using MetaMorph 4.6 software (Puchheim, Germany).22
Quantitative real-time PCR reaction
Total RNA of breast cancer tissue was isolated using TRIzol
reagent (Invitrogen), and cDNA was generated from 1,000 ng
total RNA, using a High Capacity cDNA Reverse Transcrip-
tion Kit (Applied BioSystems/ABI, Warrington, UK). Real-
time PCR assays were performed on an ABI 7500 Detection
System (ABI) using SYBR Green MasterMix (ABI). For accu-
rate normalization of quantitative data, multiple housekeeping
genes, including GAPDH, GUSB (glucuronidase-beta) and
UBC (polyubiquitin) were assayed. Primer sequences are listed
in Supporting Information Table S3.
Luminex-based protein–protein interaction assays
Luminex immunosandwich assay was performed according
to the manufacturer’s manual (The xMAP Cookbook, 3rd
Edition). Briefly, recombinant VASN was coupled on beads and
underwent on-bead removal of N-glycans and/or de-sialylation
by incubating with the enzyme PNGase F (P0704; New England
Biolabs, Ipswich, MA) at 37 C for 1 h, or α2-3 Neuraminidase
(P0728, New England Biolabs) at 37 C for 1 h. After removal
of enzymes by washing 3 times with washing buffer (PBS-BSA
1%), beads were divided equally into 96-well plates for different
reactions. In binding assay, serial dilutions of recombinant
TGF-β1 (in PBS-BSA 1%, 1 h) were used for the interaction,
and biotinylated anti-TGF-β1 antibody (1:100 in PBS-BSA 1%)
were used for detection. In control assays, biotinylated VASN
1998 ST3Gal1-modified VASN
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antibody (1:100 in PBS-BSA 1%, 1 h) was used to determine
the amount of coated VASN on the beads. To confirm the
removal of sialic acid from the recombinant coating on beads,
PNA binding studies (1:1000 in PBS-BSA 1%, 1 h) were per-
formed. For detection, beads were incubated with Streptavidin-
phycoerythrin diluted 1:50 in PBS-BSA 1% (SAPE, Millipore
Corporation, Bedford) and shaken for 30 min. After extensive
washing with PBS/BSA 1%, beads were analyzed with the Lumi-
nex 200 instrument.
Statistical analyses
All means data values were derived from three or more inde-
pendent experiments and mean (SD) are presented. Differences
between means were analyzed using Student’s t-test. p-Values of
<0.05 were considered statistically significant.
Results
Effects of altered ST3Gal1 expression on tumor growth and
vascularity
Although overexpression of ST3Gal1 has been associated
with tumoigenesis,23 however, the role of ST3Gal1 in breast
cancer progression remains poorly understood. Therefore, we
selected MCF7 to generate ST3Gal1-silenced stable clone
(MCF7/shST3Gal1) and control (MCF7/pVoid) because it
expressed the highest level of ST3Gal1 amount 10 tested
breast cancer cell (Supporting Information Fig. S1a). The
Figure 1. Effects of ST3Gal1 on tumor growth and vascular density in MCF7 engrafted tumors. (a-e) MCF7 with knockdown of ST3Gal1 and
control; (a) Western blotting (WB) analysis of ST3Gal1 in stable clones MCF7/pVoid and MCF7/shST3Gal1. (b) Tumor growth of MCF7/pVoid
and MCF7/shST3Gal1. 1 × 1018 cells of each clone were injected into the mammary fat pads of female NSG mice (n = 8) and tumor volume
was measured weekly. (c) Gross appearance and (d) tumor weight of xenografted tumors collected on days 56 after injection. (e) Blood
vessels density in the harvested tumors, as identified by IHC staining with antimouse CD31 antibody (left panel), Bar: 200 μm. The DAB-
positive areas were quantified using MetaMorph 4.6 software22 (upper panel). (f-j) MCF7 with overexpression of ST3Gal1 and control, (f ) WB
analysis of ST3Gal1 in stable clones of MCF7 transfected with pCDH-, and pCDH-ST3Gal1. The stable clones were used to generate xenograft
tumor (n = 8 for each clone) and their (g) growth curve, (h) xenografted tumors, (i) tumor weight, (J) anti CD-31 staining and quantification of
positive areas were shown.Data are represented as mean (SD). Data are analyzed by Student’s t-test. *p < 0.05; **p < 0.01, *** p < 0.001.
Yeo et al. 1999
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transfection with ST3Gal1 shRNA greatly reduced the protein
level of ST3Gal1 in MCF7/shST3Gal1 compare to MCF7/
pVoid (Fig. 1a). These stable clones were then implanted into
the mammary fat pads of NSG mice, and the tumor growth
was measured weekly. ST3Gal1 silencing significantly sup-
pressed the rate of growth (Fig. 1b) and reduced the size of
the engrafted tumors (Fig. 1c). The average weight of the
MCF7/shST3Gal1 group (505  223 mg) was twice smaller
than the MCF7/pVoid group (1,102  313 mg) (Fig. 1d). In
addition, gross appearance showed less vasculature surround-
ing tumors derived from MCF7/shST3Gal1 cells than tumors
from MCF7/pVoid (Supporting information Fig. S2a). There-
fore, we further evaluated tumor vascularity by immunohisto-
chemistry (IHC) staining with anti-CD31 antibodies (Fig. 1e).
The vascular density was quantified and the result shows that
vascularity of MCF7/shST3Gal1 tumors (0.769% vessel area/
field) was significantly reduced as compared to the MCF7/
pVoid group (2.06% vessel area/field) (Fig. 1e upper panel).
In contrast, overexpression of ST3Gal1 in MCF7 cells
(Fig. 1f) increased the rate of growth (Fig. 1g) and tended to
enhance the size of the MCF7 engrafted tumors tumor (Fig. 2h).
Although the tumor weight at 49 days was not significantly dif-
ferent between the two groups (Fig. 1i). However, overexpression
of ST3Gal1 significantly increased vascularity in the engrafted
tumors (pCDH control: pCDH-ST3Gal1, 0.486%: 1.70% vessel
area/field) (Fig. 1j upper panel). In addition, ASB-634, which
is derived from breast cancer patient-derived xenograft, was
used to generate ST3Gal1 silenced stable clones for in vivo
Figure 2. Identification of VASN as a substrate of ST3Gal1, and NanoLC-MS/MS analyses of O-glycan profiles on sVASN purified from MCF7
cells. (a) Detection of VASN in MCF7 cell extracts (110 kDa) and culture medium (sVASN, 93 kDa) by WB. (b) WB analysis of sVASN after
treated with the indicated glycosidases. (c) WB analysis of PNA lectin or VASN antibody for anti-VASN immunoprecipitated sVASN from CM of
MCF7 using siRNA- (left panel) or shRNA- (right panel) mediated ST3Gal1 silencing. (d) The merged extracted ion chromatograms are resulted
from all of their corresponding monoisotopic precursor ions (with 5 ppm tolerance) listed in Supporting Information Table S1. Note that three
very minor levels of O-glycoforms [galactosyl-core 2, sialyl-galactosyl-core 2, and sialyl elongated core 1 (peaks at 32.6, 38.9 and 39.3 min,
respectively)] are not indicated. (e) The precursor ions of sialyl-3 T and disialyl-T used for MS/MS analysis are 873.48 and 617.832+. Peak
assignment for the fragment ions are highlighted with blue arrows and the neural loss of CH3OH (−32) from specific fragment ions are
indicated with red arrow.PNA: peanut lectin agglutinin. sc: scramble siRNA control; si: ST3Gal1 siRNA.
2000 ST3Gal1-modified VASN
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engraftment experiment. The engrafted tumors from ASB-634/
shST3Gal1 displayed a paler gross appearance and less vascular
density (Supporting Information Fig. S2b-d) than the tumors
derived from ASB-634/pVoid control. Together with the obser-
vation from MCF7, we suggested ST3Gal1 mediated-tumor pro-
gression, at least in part through increased tumor angiogenesis.
VASN is a protein substrate of ST3Gal1
Peanut lectin agglutinin (PNA) recognizes the nonsialylated
Galβ1–3GalNAc-Ser/Thr core 1 O-glycan.24 To identify
ST3Gal1 substrate proteins, cell lysates from scramble control-
or ST3Gal1 siRNA-transfected cells were subjected to PNA
precipitation. The differentially PNA-binding proteins were
identified using LTQ-FT MS. VASN was identified as one of
the ST3Gal1 substrate proteins. VASN was detected in total
lysates of MCF7 cells at 110 kDa and sVASN was detected in
culture media at 93 kDa due to the cleavage in the extracellu-
lar juxtamembrane region9 (Fig. 2a). Treatment of sVASN
with PNGase F reduced the molecular weight of VASN to
slightly higher than the predicted value (71.72 kDa), and the
combination of neuraminidases further reduced it to about
71 kDa, indicating that VASN is highly glycosylated (Fig. 2b).
Moreover, VASN immunoprecipitated from culture media
derived from MCF7/siRNA (Fig. 2c, left panel), and MCF7/
shST3Gal1 (right panel) exhibited greater PNA staining than
VASN from control cells indicating the exposure of Gal-
β-(1-3) GalNAc on VASN caused by siST3Gal1 or shST3Gal1.
The mRNA level of siST3Gal1 and shST3Gal1 were reduced
to 37% and 38%, respectively, of the controls (100%)
(Supporting Information Fig. S1b). These results confirm that
VASN is a substrate protein of ST3Gal1.
LC–MS/MS analysis identified α2,3 sialylation to be
dominant O-glycan structure of VASN
To delineate the O-glycosylation of VASN, the sVASN
secreted into MCF7-conditioned medium was immunopuri-
fied using anti-VASN antibody and separated by SDS-PAGE,
followed by staining with Coomassie Brilliant Blue. The pro-
tein band corresponding to the sVASN corresponding band
was excised and subjected to in-gel enzymatic digestion with
PNGase F to remove the N-glycans, followed by releasing the
O-glycan using alkaline β-elimination.25 To stabilize the sialic
acid residues, enhance MS detection sensitivity, enable glycan
separation using reverse phase LC, and support detailed struc-
tural characterization using MS/MS, we conducted permethy-
lation26 of O-glycans and then analyzed the O-glycoforms
using LC–MS/MS. Table S1 in Supporting information sum-
marizes all of the identified O-glycoforms from sVASN, which
includes the retention times on LC/MS, mass to charge ratios
(m/z) of O-glycan ions, structural information, and relative
abundance based on the methodology described in materials
and methods. The extracted ion chromatograms of all
O-glycan ions for the measurement of relative abundance are
merged and shown in Figure 2d. Notably, around 80% of
sVASN O-glycosylation are α2,3 sialylated, with that the
majority are cancer relevant sialyl-3 T (67.44%; with a peak of
LC–MS trace at 35.3 min) and disialyl-T (7.67%; peak at
39.0 min). Both are the O-glycoforms catalyzed by ST3Gal1.
The resulting MS/MS peak assignment spectra of fragment
ions for sialyl-3 T and disialyl-T are shown in Figure 2e. Both
MS/MS spectra show predominant dissociation of the sialyl
linkage that results in the significant B fragment ion at m/z
376 and the subsequent abundant fragment ions at m/z
344 and 312 due to single and double neutral loss of CH3OH
(−32; indicated with red arrow), respectively. In the left panel,
the additional two pairs of B/Y ions (m/z 376/498 and
294/580), BZ ions (187), and Z ions (276) together suggest the
linear structure of sialyl-3 T. In the right panel, the two YY
ions of di-substituted HexNAc alditol (m/z 280) and Hex-
HexNAc alditol (484) are crucial diagnostic ions indicating a
tetra-saccharide precursor with a branching structure at the
reducing end. Together with the other peak assignments, the
spectra in the right panel suggest the structure of disialyl-T.
For the rest of O-glycans listed in Supporting Information
Table S1, their structural characterization by MS/MS spectra
with peak assignment (Supporting Information Fig. S3) also
suggested that most of the O-glycan are α2,3 sialylated. These
results confirm ST3Gal1 is the key enzyme to mediate the
O-glycoforms of VASN in MCF7.
Effects of α2,3 sialylated VASN on HUVEC tube formation
and TGF-β1 signaling
To examined whether the ST3Gal1 mediated VASN involved
in angiogenesis. First, we assessed the effects of conditioned
media (CM) from MCF7/pVoid, and MCF/shST3Gal1 on
HUVEC tube formation. HUVEC cells (15 K cells/well) were
suspended in 50% CM and 50% regular medium (EGM-2)
before addition to Matrigel precoated 48 well plates. After
14 h, CM from MCF7/shST3Gal1 significant decrease the
HUVEC tube formation ability as shown by 23% decrease of
meshes as compared to those in CM from MCF7/pVoid cells
(value set at 100%). However, the addition of VASN antibody
to CM partially prevented the CM-caused decreasing in the
formation of meshes (Fig. 3a). The prevention of VASN bind
to TGF-β1 by anti-VASN was verified and shown in Support-
ing Information Figure S5. On the other hand, TGF-β1
induced the expression of several genes relevant to angiogene-
sis in HUVEC, including FGF1, FGF13, MMP2, and MMP9
(Supporting Information Fig. S6). The induction of these
genes was suppressed by the addition of CM from MCF7/
shST3Gal1 (Fig. 3b). These results suggested that ST3Gal1
silencing and ST3Gal1-modified VASN involved in the inhibi-
tion of angiogenesis. The effect of ST3Gal1 on VASN was fur-
ther evaluated by overexpressed VASN in MCF7/pVoid and
MCF7/shST3Gal1 (Fig. 3c). CM from MCF7/shST3Gal1/
VASN markedly decreased the activation of Smad2 to 35%
(Fig. 3d) and Smad3 to 61% (Supporting Information Fig. S7)
of the control (100%) in HUVEC, respectively, indicating
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the desialylated-VASN inhibited TGF-β1/Smad signaling. More-
over, the proliferation rate of MCF7/shST3Gal1 was decreased
as compared to MCF7/pVoid and it was further reduced by
VASN overexpression in MCF7/shST3Gal1 (Supporting infor-
mation Fig. S4), these results support the notion that desialy-
lated VASN affected TGF-β1 signaling.
Effects of α2,3-sialylation on VASN and TGF-β1 interaction
It has been known that secreted VASN binds to TGF-β1 and
blocks its signaling, but whether α2,3-sialylation of VASN
affects its binding to TGF-β1 has yet to be deciphered. A
Luminex platform, as shown in the schematic illustration
in Figure 4a, was set up to determine the effect of
ST3Gal1-mediated sialylation on the binding of VASN to
TGF-β1. Briefly, recombinant VASN was coupled on beads
and underwent on-bead removal of N-glycans and/or
α2,3-sialic acid before binding studies with recombinant TGF-
β1. As shown in Figure 4b (left panel), TGF-β1 binding to
VASN-beads was enhanced by 1.8-fold when α2,3 sialic acid
was removed by treatment with α2,3 neuraminidase. In order
Figure 3. Effects of α2,3 sialylated VASN on HUVEC tube formation, and TGF-β1 mediated angiogenesis and signaling pathway.
(a) Representative phase contrast images of tube formation by HUVECs suspended in 50% CM from MCF7/shST3Gal1 or MCF7/pVoid stable
clones, with or without anti-VASN (upper panel). Scale bar = 250 μm. Numbers of meshes (as illustrated in inserts) were quantified using
ImageJ software (lower panel; n = 3). Results are represented as means (SD). Data are analyzed by Student’s t-test (*p < 0.05, ***p < 0.001).
(b) RT-PCR analysis of angiogenesis related genes in HUVEC after treated with TGF-β1 and CM from MCF7 stable clones. (c) WB analysis of VASN
in CM after transfection of the an empty vector or pin-VASN-His into MCF7/pVOID (A) and MCF7/shST3Gal1 (B). (d) WB analysis of the protein
extracts of HUVEC treated with CM from VASN over-expression in MCF7/pVoid (A) and MCF7/shST3Gal1 (B) in the present of TGF-β1 for 1 h,
GAPDH was used as control. In c-d, western blotting was performed with the indicated antibodies. WB, western blot; CM, conditioned media.
2002 ST3Gal1-modified VASN
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to rule out an effect of N-linked α2,3 sialic acid, VASN-beads
were treated with PNGase F to remove N-glycans. Treatment
with PNGase F plus α2,3-specific neuraminidases further
increased the binding to 2.2-fold. These data indicate that
α2,3 sialylation on O-linked VASN plays a major role in its
binding to TGF-β1. Meanwhile, the PNA and anti-VASN
bound to the VASN-beads after treatment with glycosidase
were also performed, indicating the successful removal of
sialic acid from VASN coated bead (Fig. 4b, middle panel),
and it did not affect the VASN amount on beads (Fig. 4b,
right panel). Similar studies were performed using neuramini-
dase (N2876, SIGMA) purchase from another source, which
catalyzes the α2,3-linked sialic acid more efficient than α2,6-
or α2,8-linked sialic acid. As shown in Figure 4c (left panel),
neuraminidase treatment enhanced the binding of TGF-β1 to
VASN by 3.2-fold. After treatment with neuraminidase plus
PNGase F, the binding remained at 2.4-fold of untreated VASN.
The slight reduction of TGF-β1 binding in the latter, suggest
that α2,3 sialylation on N-glycan may also affect the TGF-β1
binding to VASN. The PNA (Fig. 4c, middle panel) and anti-
VASN binding (Fig. 4c, right panel) to the VASN-beads after
treatment with glycosidase also performed. On the other hand,
as demonstrated by western blotting, TGF-β1-coated beads
depleted recombinant VASN more efficiently when α2–3
sialylation was removed (Supporting Information Fig. S8). This
result again indicates that removal of α2,3 sialic acid on VASN
facilities it binding to TGF-β1.
Expression levels of ST3GAL1, TGFB1 and VASN in primary
breast cancer samples and their correlation
We next examined the clinical relevance of the expression
levels of ST3GAl1, VASN, and TGFB1 in 114 pairs of primary
breast cancer and their adjacent normal tissue by qPCR. Their
clinical features of these patients were described by Fan
et al.14 As shown in Figure 5a, higher expression levels of
ST3GAL1 (p = 0.001) and TGFB1 (p < 0.0001) were detected
in the tumors than their counterpart, and the expression of
these two genes showed a positive correlation in a Pearson
Two-dimensional analysis (Fig. 5b upper panel, r = 0.322,
p < 0.001). In addition, patients with grade 3 tumor expressed
higher levels of ST3GAL1 than grade 1&2 (Supporting Infor-
mation Fig. S9). In contrast, a lower expression level of VASN
was observed in tumors than the normal tissue (p < 0.0001),
and the expression level of VASN was negatively correlated to
Figure 4. Removal of α2–3 sialic acid enhanced VASN binding to TGF-β1. (a) Flow chart of Luminex immunosandwich assay. All values
(Luminex fluorescence intensities) were normalized to wild-type control. (b) Bar chart presenting the binding fold of TGF-β1 to wild type (1×),
VASN without α2,3-sialic acid (1.8×), VASN without N-glycan (1.4×), and VASN without N-glycan and α2,3-sialic acid (2.2×). Binding fold of
PNA (middle panel) and anti-VASN to VASN-Bead (right panel) after treatment of glycosidase. (c) Bar chart presenting the binding fold of TGF-
β1 to wild type (1×), VASN without α2,3-sialic acid (3.2×), VASN without N-glycan (1.45×), and VASN without N-glycans or α2,3-sialic acid
(2.42×). Binding fold of PNA (middle panel) and anti-VASN to VASN-Bead after treatment with glycosidase.
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TGFB1 (Fig. 5b lower panel, r = −0.193, p < 0.05). The correlation
between gene expression level and relapse-free survival (RFS) of
114 patients were further evaluated. With a median follow up of
93.73 (range 0.43–137.77) months, 37 of 114 patients (32.46%)
had disease recurrence. Based on ROC curves, the best cutoff
values for stratifying into high and low gene expression levels
were selected for VASN (−2.88), TGFB1 (4.30), and ST3GAL1
(1.027). As shown in Figure 5c, patients with low levels of VASN
showed significantly shorter RFS than those with high levels of
VASN (p = 0.029, HR = 2, 95% CI = 1.087–4.651). The adverse
impact of low VASN expression was even more significant in
the patients with grade 3 tumor (p = 0.017, HR = 2.6, 95%
CI = 1.225–7.885) (right panel). Moreover, the association of
low VASN to short RFS was evident only in patients with low
expression of TGFB1 (p = 0.049, HR = 2.26, 95%
CI = 1.004–7.195) (Fig. 5d, right panel) but not those with high
expression of TGFB1 (Fig. 5d, left panel). Since ST3Gal1 is
known to be transcriptionally activated by TGF-β1,3 our findings
suggest the presence of a feedback regulatory loop in which
TGF-β1 upregulates ST3Gal1 to circumvent the negative impact
of VASN.
Combination of expression levels of ST3GAL1 with VASN, or
TGFB1 correlated with poor clinical outcome
The combined effects of ST3GAL1 and VASN, or ST3GAl1 and
TGFB1 on RFS were also evaluated. As shown in upper panel of
Figure 6a, patients with ST3GAL1HighVASNLow had a significantly
shorter RFS than those with ST3GAL1LowVASNHigh (p = 0.025,
HR = 2.69, 95% CI = 1.146–7.678). On the other hand, although
there was no significant difference in RFS between patients with
ST3Gal1HighTGFB1High and those with ST3Gal1LowTGFB1Low
(p = 0.093, HR = 2.08, 95% CI = 0.876–5.69, Fig. 6b, upper panel).
However, among patients with grade III tumors which expressed
higher levels of ST3GAL1 than grade 1&2 (Supporting Informa-
tion Fig. S9, p = 0.05), significantly shorter RFS was noted in
patients with ST3GAL1HighVASNLow (p = 0.01, HR = 4.20, 95%
Figure 5. Expression levels of ST3GAL1, TGFB1 and VASN in 114 primary breast cancer samples and their correlation. (a) Expression levels of
ST3GAL1, VASN and TGFB1 in tumor and adjacent normal tissue. (b) Pearson’s correlation analysis for TGFB1 and ST3GAL1 (upper panel), or
TGFB1 and VASN (lower panel). (c) RFS Kaplan–Meier plots of low and high VASN expression in overall study population (left panel) and in
patients with grade 3 tumor (right panel). (d) Negative effect of VASN associated to high expression of TGFB1 high (left panel) and low
expression of TGFB1 (right panel). Gene expression level was determined by RT-PCR. Each scatter dot represents the value of minus delta
threshold cycle (-ΔCt) normalized to the average of three internal controls: GAPDH, GUSB and UBC. Expression level of each gene is stratified
to high and low, according to ROC analysis. HR, Hazard Ratio. Statistical significance is determined by student’s t-test. ***p < 0.001.
2004 ST3Gal1-modified VASN
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CI = 1.457–16.39) or ST3Gal1HighTGFB1High (p = 0.07, HR = 2.93,
95% CI = 0.906–10.43) than their counterparts (lower panels in
Figs. 6a and 6b).
Furthermore, the association of these three genes with
clinical-pathological parameters in 114 patients was analyzed.
As shown in Supporting Information Table S2, low expression
of VASN was associated with a hazard ratio (HR) of 2.16 for
tumor recurrence (p = 0.019, 95% CI: 1.13–4.14). High expres-
sions of ST3GAL1 and TGFB1 individually showed a higher
risk for recurrence (HR = 2.28), albeit the difference did not
reach statistical significance (p = 0.059, 95% CI: 0.97–5.38).
More importantly, multivariate Cox Proportional-Hazards
Regression survival analysis revealed that low VASN expres-
sion was an independent risk factor for relapse, with a HR of
2.06 (p = 0.003, 95% CI: 1.07–3.92).
Discussion
Overexpression of ST3Gal1 has been associated with mammary
tumorigenesis.23 In noncancer cells, ST3Gal1 mediated-
sialylation of CD43 was found associated with anti-CD43-in-
duced CD8+ T Lymphocyte apoptosis,27 and decreased
CD8αβ-MHCI binding avidity.28 However, the substrate of
ST3Gal1 and mechanism that help to promote tumor progres-
sion is so far ill defined. By combining PNA-precipitation with
LTQ-FT MS, a set of ST3Gal1 substrates have been identified
and being investigated. Among them, ST3Gal1-mediated sialy-
lation of GFRA1 and CD55 was found to promote tumor
growth, and evade immune surveillance, respectively. In our
study, we demonstrated that the ST3Gal1 mediated-O-linked
sialylation of VASN diminished its binding to TGF-β1. Five
N-glycosylation sites and four O-glycosylation sites (318, 487,
516, 567) were identified in the sequence.29 However, more
than 30 potential O-glycosylation sites on VASN were pre-
dicted by the NetOGLyc 4.0. The predicted sites were distrib-
uted throughout the protein sequence with many crowded near
the EGF-like domain, making it very challenging to decipher
the precise O-linked glycan site of VASN that modulates its
interaction with TGF-β1. Nonetheless, our demonstration of
the importance of ST3Gal1-mediated α2,3-sialylation of VASN
in modulating tumor angiogenesis illustrates the importance of
delineating the involved O-linked glycosylation sites on VASN
in future studies.
TGF-β is a key cytokine in maintaining tissue homeosta-
sis.30,31 However, accumulating evidence indicates that it also
augments tumor growth, enhances invasion and metastasis32,33
by modulating angiogenesis,34 promotes epithelial to mesen-
chymal transition,35 suppresses immune responses36 and
enhances ECM production. High levels of circulating TGF-β1
was detected in the plasma of patients with cancer,37,38 which
correlated with poor prognosis with increased probability of
relapse.39,40 Moreover, upregulation of TGF-β1 has been noted
in breast cancer specimens41 and increase the risk of advanced
breast cancer39 with the promotion of angiogenesis.42 Among
breast cancer cell lines, MCF7 cells expressed higher levels of
TGF-β1.43 A clone derived from MCF7 cells and secreted
greater than 10-fold of TGF-β1 was more tumorigenic than the
parental line, and tumor formation was abrogated by the
administration of a TGF-β1 neutralizing antibody.41 Gene
knocks out of TGF-β or its receptors and downstream signal-
ing proteins led to embryonic lethality due to vascular
Figure 6. Correlation of combination of ST3GAL1/VASN and ST3GAL1/TGFB1 with RFS in overall study population (upper panel of a, b) and in
patients with grade 3 tumor (lower panel of a, b). (a) Combination of ST3GAL1 and VASN. (b) Combination of TGFB1 and ST3GAL1. (c) Schematic
illustration showing that α2,3 sialylation of VASN by ST3Gal1 reduces the ability of secreted VASN to trap TGF-β1. HR, Hazard Ratio.
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defects.44 The correlation of TGFB1 and ST3GAL was reported
in glioblastoma by Chong et al., and they demonstrated that
ST3Gal1 was transcriptionally activated by TGF-β1 using chro-
matin immunoprecipitation combined with anti-pSmad2 anti-
body.3,45 In our study, we further demonstrated that TGF-β1
upregulates ST3Gal1 to circumvent the negative impact of
VASN, which in turn trigger MMPs, FGFs expression to sup-
port angiogenesis in tumor. This finding reveals a noval
glycosylation-mediated feedback loop to the known regulatory
mechanisms of the TGF-β/Smad signaling system.46
Breast cancer is the most common cancer and the leading
cause of death in women worldwide. Although the diagnosis
and treatment of primary tumors have markedly improved,
metastasis and/or recurrence of breast cancer remains the
major cause of death.47 Thus, it is crucial to identify novel
biomarkers for prognostication and therapy. In 114 breast
cancer patients, we found that VASN was significantly down-
regulated in tumor compared to adjacent normal tissue, while
ST3GAL1 and TGFB1 highly expressed in breast cancer.
Kaplan–Meier analysis for RFS showed that lower VASN
expression significantly correlated with a higher risk of breast
cancer recurrence, suggesting that VASN probably acts as a
tumor suppressor in breast cancer. Multivariant analyses indi-
cated that VASN was an independent risk factor for breast
cancer recurrence. On the other hand, there was a trend for
an association of poorer RFS with higher expression of either
ST3Gal1 or TGF-β1. Importantly, the combination of low
VASN and high ST3Gal1 expression increased the risk of the
recurrence of disease, as demonstrated by a higher HR.
In summary, we have demonstrated for the first time a
molecular mechanism underlying angiogenesis modulated by
ST3Gal1-mediated sialylation of VASN, supporting the notion
that inhibition of ST3Gal1 is a promising new strategy for
cancer therapy.
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